Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for cancer and obesity. The company's mission is to apply inventive scientific approaches to well-understood biological pathways to address serious illnesses. Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, United States.

The company's pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4 for the treatment of various solid tumors, such as head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Additionally, Corbus is developing CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Another candidate, CRB-601, is an anti-integrin monoclonal antibody designed to block the activation of TGFβ expressed on cancer cells.

Recent developments include Corbus Pharmaceuticals announcing broad alignment with the FDA on the registration pathway for CRB-701 in second-line HNSCC and cervical cancer, with updated clinical data for CRB-701 slated for presentation at ASCO 2026. The company also reported the last patient first visit in the CANYON-1 study of CRB-913 for obesity in April 2026, following promising Phase 1a study results that demonstrated a favorable safety profile and emerging evidence of weight loss. Yuval Cohen, Ph.D., leads the company as its Chief Executive Officer. Corbus Pharmaceuticals is positioned as a clinical-stage entity within the biotechnology sector, focusing on addressing significant unmet medical needs.